Edgar Filing: ACELRX PHARMACEUTICALS INC - Form DEFA14A

ACELRX PHARMACEUTICALS INC Form DEFA14A April 23, 2018

SCHEDULE 14A INFORMATION

Proxy Statement Pursuant to Sec	ction 14(a) of the
Securities Exchange Act of 1934	
(Amendment No.)	
Filed by the Registrant	Filed by a Party other than the Registrant
Check the appropriate box:	
Preliminary Proxy Statement	
Confidential, for Use of the Con	nmission Only (as permitted by Rule 14a-6(e)(2))
Definitive Proxy Statement	
Definitive Additional Materials	
Soliciting Material Pursuant to § 2	240.14a-12
AcelRx Pharmaceuticals, Inc. (Name of Registrant as Specified	In Its Charter)
(Name of Person(s) Filing Proxy	Statement if Other Than the Registrant)
Payment of Filing Fee (Check the	appropriate box)
No fee required.	
Fee computed on table below per	Exchange Act Rules 14a-6(i)(1) and 0-11.
Title of each class of securities 1.	to which transaction applies:
2. Aggregate number of securities	to which transaction applies:

Edgar Filing: ACELRX PHARMACEUTICALS INC - Form DEFA14A

Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (Set forth the amount on which the filing fee is calculated and state how it was determined): 3.
Proposed maximum aggregate value of transaction: 4.
5. Total fee paid:
Fee paid previously with preliminary materials.
Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
Amount Previously Paid: 6.
Form, Schedule or Registration Statement No.: 7.
Filing Party: 8.
Date Filed: 9.

Edgar Filing: ACELRX PHARMACEUTICALS INC - Form DEFA14A